| __timestamp | Bausch Health Companies Inc. | BioCryst Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 246000000 | 51796000 |
| Thursday, January 1, 2015 | 582800000 | 72758000 |
| Friday, January 1, 2016 | 455000000 | 61008000 |
| Sunday, January 1, 2017 | 366000000 | 66962000 |
| Monday, January 1, 2018 | 414000000 | 84888000 |
| Tuesday, January 1, 2019 | 471000000 | 107068000 |
| Wednesday, January 1, 2020 | 452000000 | 122964000 |
| Friday, January 1, 2021 | 465000000 | 208808000 |
| Saturday, January 1, 2022 | 529000000 | 253297000 |
| Sunday, January 1, 2023 | 604000000 | 216566000 |
Infusing magic into the data realm
In the competitive landscape of pharmaceuticals, research and development (R&D) spending is a critical indicator of a company's commitment to innovation. Over the past decade, Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc. have demonstrated contrasting strategies in their R&D investments. From 2014 to 2023, Bausch Health consistently allocated a significant portion of its resources to R&D, with a notable increase of approximately 145% in spending, peaking in 2023. In contrast, BioCryst Pharmaceuticals, while starting with a modest R&D budget, showed a remarkable growth trajectory, increasing its R&D expenses by over 300% during the same period. This strategic focus underscores the importance of R&D in driving pharmaceutical advancements and maintaining competitive advantage. As these companies continue to innovate, their R&D investments will likely play a pivotal role in shaping their future success.
Amgen Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Who Prioritizes Innovation? R&D Spending Compared for Bristol-Myers Squibb Company and Bausch Health Companies Inc.
Research and Development Investment: argenx SE vs BioCryst Pharmaceuticals, Inc.
Neurocrine Biosciences, Inc. vs Bausch Health Companies Inc.: Strategic Focus on R&D Spending
Intra-Cellular Therapies, Inc. vs BioCryst Pharmaceuticals, Inc.: Strategic Focus on R&D Spending
Research and Development: Comparing Key Metrics for Grifols, S.A. and Bausch Health Companies Inc.
Research and Development Investment: Corcept Therapeutics Incorporated vs BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: CRISPR Therapeutics AG vs BioCryst Pharmaceuticals, Inc.
Research and Development Expenses Breakdown: Bausch Health Companies Inc. vs Viridian Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Bausch Health Companies Inc. and BioCryst Pharmaceuticals, Inc.
Comparing Innovation Spending: Agios Pharmaceuticals, Inc. and BioCryst Pharmaceuticals, Inc.
Who Prioritizes Innovation? R&D Spending Compared for BioCryst Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.